Center for Genetic Engineering and Biotechnology
The Center for Genetic Engineering and Biotechnology (Spanish: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba. FoundingIn 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World.[1]: 132 Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy.[1]: 132 Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.[1]: 132 ActivityIn 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[2] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[2] As of 2017, CIGB had 1,600 employees and sold 21 products internationally.[1]: 138 As of 2020, CIGB had two joint ventures with China.[1]: 143 It is responsible for creating the Abdala vaccine.[3][4][5] The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6] See alsoReferences
External links
|
||||||||||||||||
Portal di Ensiklopedia Dunia
